在小鼠中,Pediococcus pentosaceus Li05对腹占主导地位的刺激性肠综合征的保护作用
Youhe Wu1, Shengjie Li1, Longxian Lv1
1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd., Hangzhou City 310003, China. ljli@zju.edu.cn.
Pediococcus pentosaceus Li05 (Li05) 益生菌有效降低了腹,炎症和腹部敏感性,在患有腹刺激性肠综合征 (IBS-D) 的老鼠中. 它还调节了肠道微生物群和新陈代谢,显示了IBS-D管理的前景.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- Pediococcus pentosaceus Li05 (Li05) 显示可能导致肠道疾病.
- Li05在缓解腹占主导地位的刺激性肠综合征 (IBS-D) 的机制尚不清楚.
研究的目的:
- 为了研究Li05在IBS-D.小鼠模型中的作用和机制.
- 评估Li05对炎症,肠道微生物群和新陈代谢的影响.
主要方法:
- 在老鼠中,IBS-D被诱导使用包装束应力和酸.
- 通过测量体重减轻,内脏敏感性,炎症标志物,5-HT3BR表达,肠道微生物群组成和代谢概况来评估Li05的效果.
主要成果:
- 在IBS-D大鼠中,Li05缓解了体重减轻,内脏敏感和腹.
- 通过降低促炎性细胞因子,Li05减少了肠道和全身炎症.
- Li05调节了肠道微生物群的组成,改变了脂肪酸和氨基酸代谢.
- Li05降低了5基三胺受体3B (5-HT3BR) 表达的调节.
结论:
- Li05通过减少炎症和调节肠道微生物群和新陈代谢,有效改善IBS-D症状.
- Li05显示出作为治疗IBS-D的益生菌的潜力.
更多相关视频
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS